US discussion on value-based contracts is well underway, says report

A white paper with input from a host of experts from big pharma has looked into the extent to which the US market is moving towards value-based contracts that reward manufacturers on outcomes rather than volume.

The report, from event provider eyeforpharma has been published ahead of the Data, Evidence and Access Summit 2017 taking place in Philadelphia in November, and is titled  Is the US market ready for value-based contracting?

Fee-for service arrangements in the USA mean that payment is made upon service and is therefore tied to volume. This system does not currently track quality, though the paper notes that moves towards linking the price of treatments, including pharmaceutical interventions, to the outcomes that they produce, are underway.

Private and public sectors exploring change